What Can hiPSC-Cardiomyocytes Teach Us about Modeling Complex Human Disease Phenotypes?
Using induced pluripotent stem cell-derived cardiomyocytes to predict patient-specific responses to drug treatments requires that they maintain inter-individual variability for RNA expression and recapitulate phenotypic responses in vitro. In this issue of Cell Stem Cell, Matsa et al. (2016) show that expression differences between hiPSC-cardiomyocytes provide a personalized drug testing platform to evaluate potential efficacy and cardiotoxicity.